Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

592 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N. Yamashita T, et al. Among authors: saji s. J Clin Oncol. 2025 Jan 9:JCO2401888. doi: 10.1200/JCO-24-01888. Online ahead of print. J Clin Oncol. 2025. PMID: 39787453
Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy.
Ito M, Amari M, Sato A, Hikichi M, Tsurumi N, Otofuji H, Saji S. Ito M, et al. Among authors: saji s. Breast Cancer Res Treat. 2024 Oct 17. doi: 10.1007/s10549-024-07509-1. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39417907
Effect of Combined Exercise and Nutrition Interventions During Inpatient Chemotherapy in Acute Leukemia and Malignant Lymphoma Patients: A Randomized Controlled Trial.
Kasahara R, Morishita S, Fujita T, Jinbo R, Kubota J, Takano A, Takahashi S, Kisara S, Jinbo K, Yamamoto Y, Kakuta M, Kai T, Shiga Y, Kimura H, Furukawa M, Saji S. Kasahara R, et al. Among authors: saji s. Nutr Cancer. 2025;77(1):115-123. doi: 10.1080/01635581.2024.2406043. Epub 2024 Sep 19. Nutr Cancer. 2025. PMID: 39300733 Clinical Trial.
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. Bardia A, et al. J Clin Oncol. 2024 Sep 12:JCO2400920. doi: 10.1200/JCO.24.00920. Online ahead of print. J Clin Oncol. 2024. PMID: 39265124
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
Dent RA, Kim SB, Oliveira M, Barrios C, O'Shaughnessy J, Isakoff SJ, Saji S, Freitas-Junior R, Philco M, Bondarenko I, Lian Q, Bradley D, Hinton H, Wongchenko MJ, Reilly SJ, Turner N. Dent RA, et al. Among authors: saji s. Clin Cancer Res. 2024 Oct 1;30(19):4329-4338. doi: 10.1158/1078-0432.CCR-24-0465. Clin Cancer Res. 2024. PMID: 39058425 Free PMC article. Clinical Trial.
592 results